Lipoprotein metabolism and lipid management in chronic kidney disease.
暂无分享,去创建一个
F. Kronenberg | A. Cheung | B. C. Kwan | S. Beddhu | B. Kwan
[1] W. Feeman. Statin-fibrate combination therapy. , 2008, The American journal of cardiology.
[2] S. Feasson,et al. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals : a randomised placebo-controlled trial. , 2008 .
[3] F. Kronenberg,et al. In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients. , 2007, Kidney international.
[4] C. Wanner,et al. The effect of fluvastatin on cardiac outcomes in patients with moderate to severe renal insufficiency: a pooled analysis of double-blind, randomized trials. , 2007, International journal of cardiology.
[5] Richard Platt,et al. Risk factors for statin‐associated rhabdomyolysis , 2007, Pharmacoepidemiology and drug safety.
[6] F. Kronenberg,et al. Role of the kidney in the metabolism of apolipoprotein A-IV: influence of the type of proteinuria Published, JLR Papers in Press, June 20, 2006. , 2006, Journal of Lipid Research.
[7] Mason W Freeman,et al. Scavenger receptors in atherosclerosis: beyond lipid uptake. , 2006, Arteriosclerosis, thrombosis, and vascular biology.
[8] C. Schaefer,et al. Direct Adsorption of Low‐Density Lipoprotein by DALI‐LDL‐Apheresis: Results of a Prospective Long‐term Multicenter Follow‐up Covering 12 291 Sessions , 2006, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.
[9] F. Kronenberg,et al. Carotid plaques and their predictive value for cardiovascular disease and all-cause mortality in hemodialysis patients considering renal transplantation: a decade follow-up. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[10] J. Avorn,et al. Poor short-term survival and low use of cardiovascular medications in elderly dialysis patients after acute myocardial infarction. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[11] F. Kronenberg,et al. Apolipoprotein A-IV predicts progression of chronic kidney disease: the mild to moderate kidney disease study. , 2006, Journal of the American Society of Nephrology : JASN.
[12] F. Kronenberg,et al. Delayed In Vivo Catabolism of Intermediate-Density Lipoprotein and Low-Density Lipoprotein in Hemodialysis Patients as Potential Cause of Premature Atherosclerosis , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[13] M. Hayden,et al. Gene therapy for lipoprotein lipase deficiency: working toward clinical application. , 2005, Human gene therapy.
[14] T. Lehtimäki,et al. HDL enhances oxidation of LDL in vitro in both men and women , 2005, Lipids in Health and Disease.
[15] P. Raggi,et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. , 2005, Kidney international.
[16] F. Kronenberg,et al. Immunohistochemical localization of apolipoprotein A-IV in human kidney tissue. , 2005, Kidney international.
[17] W. März,et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. , 2005, The New England journal of medicine.
[18] F. Zannad,et al. Effect of rosuvastatin on outcomes in chronic haemodialysis patients – design and rationale of the AURORA study , 2005, Current controlled trials in cardiovascular medicine.
[19] P. Raggi,et al. Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. , 2005, American heart journal.
[20] J. van der Palen,et al. Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: a randomised‐controlled trial , 2005, Journal of internal medicine.
[21] C. Böger,et al. Effect of HMG-CoA-reductase inhibitors on survival in type 2 diabetes patients with end stage diabetic nephropathy. , 2005, European journal of medical research.
[22] F. Kronenberg. Dyslipidemia and nephrotic syndrome: recent advances. , 2005, Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation.
[23] N. Powe,et al. High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in dialysis patients. , 2005, Journal of the American Society of Nephrology : JASN.
[24] Dick M. Goedhart,et al. Long-term fluvastatin reduces the hazardous effect of renal impairment on four-year atherosclerotic outcomes (a LIPS substudy). , 2005, The American journal of cardiology.
[25] J. Bragg-Gresham,et al. HMG-coenzyme a reductase inhibitor use is associated with mortality reduction in hemodialysis patients. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[26] Jeannie K. Lee,et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: A Double-Blind, Placebo-Controlled Study of Extended-Release Niacin on Atherosclerosis Progression in Secondary Prevention Patients Treated With Statins , 2004, Circulation.
[27] Matthias John,et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs , 2004, Nature.
[28] M. Sarnak,et al. Apolipoprotein A-I, B-100, and B-48 metabolism in subjects with chronic kidney disease, obesity, and the metabolic syndrome. , 2004, Metabolism: clinical and experimental.
[29] P. Dupont,et al. Lipid and apoprotein changes during atorvastatin up-titration in hemodialysis patients with hypercholesterolemia: a placebo-controlled study. , 2004, Clinical nephrology.
[30] M. Bennett,et al. Role of apoptosis in atherosclerosis and its therapeutic implications. , 2004, Clinical science.
[31] C. Wanner,et al. Effect of dialysis flux and membrane material on dyslipidaemia and inflammation in haemodialysis patients. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[32] John Simes,et al. Effect of Pravastatin on Cardiovascular Events in People With Chronic Kidney Disease , 2004, Circulation.
[33] F. Kronenberg. Epidemiology, pathophysiology and therapeutic implications of lipoprotein(a) in kidney disease , 2004, Expert review of cardiovascular therapy.
[34] H. Bloomfield,et al. Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency. , 2004, Kidney international.
[35] J. Mckenney. New perspectives on the use of niacin in the treatment of lipid disorders. , 2004, Archives of internal medicine.
[36] S. Yusuf,et al. Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: results of the HOPE study. , 2004, Kidney international.
[37] A. D'Angelo,et al. Lipoprotein(a)-Associated Atherothrombotic Risk in Hemodialysis Patients , 2004, American Journal of Nephrology.
[38] F. Kronenberg,et al. The apolipoprotein(a) size polymorphism is associated with nephrotic syndrome. , 2004, Kidney international.
[39] N. Powe,et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. , 2004, JAMA.
[40] M. Linton,et al. Apolipoprotein AI as therapy for atherosclerosis: does the future of preventive cardiology include weekly injections of the HDL protein? , 2003, Molecular interventions.
[41] A. Krentz. Lipoprotein abnormalities and their consequences for patients with Type 2 diabetes , 2003, Diabetes, obesity & metabolism.
[42] T. Littlewood,et al. Apoptotic cell death in atherosclerosis , 2003, Current opinion in lipidology.
[43] F. Kronenberg,et al. Apolipoprotein(a) isoform-specific changes of lipoprotein(a) after kidney transplantation , 2003, European Journal of Human Genetics.
[44] G. Asmus,et al. Different impact of biomarkers as mortality predictors among diabetic and nondiabetic patients undergoing hemodialysis. , 2003, Journal of the American Society of Nephrology : JASN.
[45] C. Baigent,et al. Study of Heart and Renal Protection (SHARP). , 2003, Kidney international. Supplement.
[46] A. Jardine,et al. Why do we need a statin trial in hemodialysis patients? , 2003, Kidney international. Supplement.
[47] R. Collins,et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial , 2003, The Lancet.
[48] W. März,et al. Risk for myopathy with statin therapy in high-risk patients. , 2003, Archives of internal medicine.
[49] F. Sacks,et al. Pravastatin for Secondary Prevention of Cardiovascular Events in Persons with Mild Chronic Renal Insufficiency , 2003, Annals of Internal Medicine.
[50] K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[51] N. Powe,et al. Small Apolipoprotein(a) Size Predicts Mortality in End-Stage Renal Disease: The CHOICE Study , 2002, Circulation.
[52] M. Navab,et al. Oxidized lipids as mediators of coronary heart disease , 2002, Current opinion in lipidology.
[53] AndrewJ. S. Coats. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.
[54] P. Raggi,et al. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. , 2002, Kidney international.
[55] A. R. Morton,et al. Apolipoprotein(a) Phenotype and Lipoprotein(a) Level Predict Peritoneal Dialysis Patient Mortality , 2002, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.
[56] N. Powe,et al. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. , 2002, Journal of the American Society of Nephrology : JASN.
[57] K. Iseki,et al. Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. , 2002, Kidney international.
[58] F. Kronenberg,et al. Apolipoprotein A-IV serum concentrations are elevated in patients with mild and moderate renal failure. , 2002, Journal of the American Society of Nephrology : JASN.
[59] S. Yusuf. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .
[60] B. Kestenbaum,et al. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. , 2002, Kidney international.
[61] E. Bolson,et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. , 2001, The New England journal of medicine.
[62] I. Hamilton-Craig,et al. Statin‐associated myopathy , 2001, The Medical journal of Australia.
[63] M. Emoto,et al. Diabetes mellitus, aortic stiffness, and cardiovascular mortality in end-stage renal disease. , 2001, Journal of the American Society of Nephrology : JASN.
[64] W. Bloembergen,et al. Prevalence and clinical correlates of coronary artery disease among new dialysis patients in the United States: a cross-sectional study. , 2001, Journal of the American Society of Nephrology : JASN.
[65] Y. Zhao,et al. The relationship between plasma apolipoprotein A-IV levels and coronary heart disease. , 2001, Chinese medical journal.
[66] R. Virmani,et al. Apoptosis in atherosclerosis. Does it contribute to plaque instability? , 2001, Cardiology clinics.
[67] P. Wilson,et al. Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham Heart Study. , 2001, Atherosclerosis.
[68] M. Boaz,et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial , 2000, The Lancet.
[69] M. Haberal,et al. Effect of apolipoprotein E polymorphism on serum lipid, lipoproteins, and atherosclerosis in hemodialysis patients. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[70] F. Kronenberg,et al. Low apolipoprotein A-IV plasma concentrations in men with coronary artery disease. , 2000, Journal of the American College of Cardiology.
[71] M. Rocco,et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. , 2000, Kidney international.
[72] S. Grundy,et al. Alpha-tocopherol supplementation decreases the oxidative susceptibility of LDL in renal failure patients on dialysis therapy. , 2000, Atherosclerosis.
[73] F. Kronenberg,et al. Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. , 2000, Journal of the American Society of Nephrology : JASN.
[74] Y. Kawaguchi,et al. Role of hepatic lipase in intermediate-density lipoprotein and small, dense low-density lipoprotein formation in hemodialysis patients. , 1999, Kidney international. Supplement.
[75] S. Watanabe,et al. Lipoprotein(a) as a risk factor for coronary artery disease in hemodialysis patients. , 1999, Kidney international. Supplement.
[76] H. Otani,et al. Effect of vitamin E on lipid metabolism and atherosclerosis in ESRD patients. , 1999, Kidney international. Supplement.
[77] S. Nishi,et al. Lipoprotein(a) is a predictor for cardiovascular mortality of hemodialysis patients. , 1999, Kidney international. Supplement.
[78] F. Kronenberg,et al. Lipoprotein(a) plasma concentrations after renal transplantation: a prospective evaluation after 4 years of follow-up. , 1999, Atherosclerosis.
[79] H. Milionis,et al. Apolipoprotein(a) phenotypes and lipoprotein(a) concentrations in patients with renal failure. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[80] F. Kronenberg,et al. The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up. , 1999, Journal of the American Society of Nephrology : JASN.
[81] P. Stenvinkel,et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. , 1999, Kidney international.
[82] C. Wanner,et al. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. , 1999, Kidney international.
[83] F. Kronenberg,et al. Genetics and metabolism of lipoprotein(a) and their clinical implications (Part 1). , 1999, Wiener klinische Wochenschrift.
[84] C. Knoop,et al. Drug treatment of lipid disorders. , 1999, The New England journal of medicine.
[85] R. Schwartz,et al. Apoptosis. Basic concepts and implications in coronary artery disease. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[86] R. Havel,et al. Evaluation of an immunoseparation method for quantitative measurement of remnant-like particle-cholesterol in serum and plasma. , 1998, Clinical chemistry.
[87] P. Marquet,et al. Decrease of serum paraoxonase activity in chronic renal failure. , 1998, Journal of the American Society of Nephrology : JASN.
[88] J. Haddow,et al. Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies. , 1998, Clinical chemistry.
[89] T. Rabelink,et al. Evidence for increased synthesis of lipoprotein(a) in the nephrotic syndrome. , 1998, Journal of the American Society of Nephrology : JASN.
[90] T. Shoji,et al. Intermediate-density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients. , 1998, Journal of the American Society of Nephrology : JASN.
[91] P. Stenvinkel,et al. Apo(a)-isoform size, nutritional status and inflammatory markers in chronic renal failure. , 1998, Kidney international.
[92] D. Levy,et al. Prediction of coronary heart disease using risk factor categories. , 1998, Circulation.
[93] A. Tall,et al. Plasma lipid transfer proteins, high-density lipoproteins, and reverse cholesterol transport. , 1998, Annual review of nutrition.
[94] F. Kronenberg,et al. Apolipoprotein B, fibrinogen, HDL cholesterol, and apolipoprotein(a) phenotypes predict coronary artery disease in hemodialysis patients. , 1997, Journal of the American Society of Nephrology : JASN.
[95] M. Árnadóttir. Pathogenesis of dyslipoproteinemia in renal insufficiency: the role of lipoprotein lipase and hepatic lipase. , 1997, Scandinavian journal of clinical and laboratory investigation.
[96] C. Gazzaruso,et al. Increased plasma concentrations of lipoprotein(a) for every phenotype of apolipoprotein(a) in patients with chronic renal failure treated by hemodialysis , 1996 .
[97] K. Iseki,et al. Predictors of stroke in patients receiving chronic hemodialysis. , 1996, Kidney international.
[98] Helen H. Hobbs,et al. Identification of Scavenger Receptor SR-BI as a High Density Lipoprotein Receptor , 1996, Science.
[99] Shin-Wook Kang,et al. Impact of Nutritional Status on Serum Lipoprotein (A) Concentration in Patients Undergoing Continuous Ambulatory Peritoneal Dialysis , 1996, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.
[100] F. Kronenberg,et al. Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. , 1995, Journal of the American Society of Nephrology : JASN.
[101] M. Seed,et al. Lipids and lipoprotein(a) as risk factors for vascular disease in patients on renal replacement therapy. , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[102] C. Wanner,et al. Protein loss and genetic polymorphism of apolipoprotein(a) modulate serum lipoprotein(a) in CAPD patients. , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[103] M. Kishino,et al. Effect of alpha-tocopherol on in vitro and in vivo metabolism of low-density lipoproteins in haemodialysis patients. , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[104] G. Schonfeld,et al. The effects of fibrates on lipoprotein and hemostatic coronary risk factors. , 1994, Atherosclerosis.
[105] F. Kronenberg,et al. Apolipoprotein(a) phenotype-associated decrease in lipoprotein(a) plasma concentrations after renal transplantation. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.
[106] F. Kronenberg,et al. Apolipoprotein(a) phenotypes predict the risk for carotid atherosclerosis in patients with end-stage renal disease. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.
[107] P. Gambert,et al. Comparative effects of purified apolipoproteins A-I, A-II, and A-IV on cholesteryl ester transfer protein activity. , 1994, Journal of lipid research.
[108] D. Rader,et al. Elevated Plasma Lipoprotein(a) in Patients with the Nephrotic Syndrome , 1993, Annals of Internal Medicine.
[109] A. Cheung,et al. Atherogenic lipids and lipoproteins in hemodialysis patients. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[110] F. Kronenberg,et al. Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a). , 1993, The Journal of clinical investigation.
[111] M. Sentí,et al. Serum lipoprotein(a) concentration in patients with chronic renal failure receiving haemodialysis: influence of apolipoprotein (a) genetic polymorphism. , 1993, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[112] R. Heyka,et al. Lipoprotein(a) Is an Independent Risk Factor for Cardiovascular Disease in Hemodialysis Patients , 1992, Circulation.
[113] R. Krauss,et al. Differential effects of nicotinic acid in subjects with different LDL subclass patterns. , 1992, Atherosclerosis.
[114] M. Sentí,et al. Lipoprotein abnormalities in hyperlipidemic and normolipidemic men on hemodialysis with chronic renal failure. , 1992, Kidney international.
[115] E. Lowrie,et al. Commonly measured laboratory variables in hemodialysis patients: relationships among them and to death risk. , 1992, Seminars in nephrology.
[116] G. Utermann,et al. Plasma apolipoprotein A‐IV metabolism in patients with chronic renal disease , 1992, European journal of clinical investigation.
[117] A. del Río. [Lipoprotein (a)]. , 1991, Medicina clinica.
[118] P. Attman,et al. Lipid and apolipoprotein profiles of uremic dyslipoproteinemia--relation to renal function and dialysis. , 1991, Nephron.
[119] M. King,et al. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. , 1990, Circulation.
[120] J. Fruchart,et al. Human apolipoprotein A-IV binds to apolipoprotein A-I/A-II receptor sites and promotes cholesterol efflux from adipose cells. , 1990, The Journal of biological chemistry.
[121] E G Lowrie,et al. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. , 1990, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[122] I. Goldberg,et al. Lipoprotein ApoC-II activation of lipoprotein lipase. Modulation by apolipoprotein A-IV. , 1990, The Journal of biological chemistry.
[123] Ronald M. Krauss,et al. A PROPOSED GENETIC MARKER FOR CORONARY HEART DISEASE RISK , 1990 .
[124] A. Hamsten,et al. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid , 1989, Journal of internal medicine.
[125] B. Gordon,et al. Plasmin catalyzes binding of lipoprotein (a) to immobilized fibrinogen and fibrin. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[126] G. Rosenhamer,et al. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. , 2009, Acta medica Scandinavica.
[127] S. Grundy,et al. Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia. , 1987, The American journal of medicine.
[128] S. Grundy,et al. Fibric acids: effects on lipids and lipoprotein metabolism. , 1987, The American journal of medicine.
[129] M. Seishima,et al. An increased apo A-IV serum concentration of patients with chronic renal failure on hemodialysis. , 1987, Clinica chimica acta; international journal of clinical chemistry.
[130] J. Stamler,et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. , 1986, Journal of the American College of Cardiology.
[131] A. Gotto,et al. Apolipoprotein A-IV. A determinant for binding and uptake of high density lipoproteins by rat hepatocytes. , 1986, The Journal of biological chemistry.
[132] M. Lefevre,et al. The role of apolipoprotein A-IV in reverse cholesterol transport studied with cultured cells and liposomes derived from an ether analog of phosphatidylcholine. , 1986, Biochimica et biophysica acta.
[133] M. Brown,et al. A receptor-mediated pathway for cholesterol homeostasis. , 1986, Science.
[134] J. Albers,et al. Activation of lecithin: cholesterol acyltransferase by apolipoproteins E-2, E-3, and A-IV isolated from human plasma. , 1985, Biochimica et biophysica acta.
[135] R. Zechner,et al. The in vitro formation of HDL2 during the action of LCAT: the role of triglyceride-rich lipoproteins. , 1985, Journal of lipid research.
[136] G. Utermann,et al. Activation of lecithin: cholesterol acyltransferase by human apolipoprotein A-IV. , 1985, The Journal of biological chemistry.
[137] M. Brown,et al. Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. , 1983, Annual review of biochemistry.
[138] P. Nestel,et al. Increased lipoprotein-remnant formation in chronic renal failure. , 1982, The New England journal of medicine.
[139] P. Degoulet,et al. Mortality risk factors in patients treated by chronic hemodialysis. Report of the Diaphane collaborative study. , 1982, Nephron.
[140] H. Mabuchi,et al. Intermediate‐density Lipoprotein and Cholesterol‐rich Very Low Density Lipoprotein in Angiographically Determined Coronary Artery Disease , 1981, Circulation.
[141] A Cryer,et al. Tissue lipoprotein lipase activity and its action in lipoprotein metabolism. , 1981, The International journal of biochemistry.
[142] L. Simons,et al. Impaired plasma triglyceride clearance as a feature of both uremic and posttransplant triglyceridemia. , 1980, Kidney international.
[143] D. Cattran,et al. Defective triglyceride removal in lipemia associated with peritoneal dialysis and haemodialysis. , 1976, Annals of Internal Medicine.
[144] D. Bilheimer,et al. On the metabolic conversion of human plasma very low density lipoprotein to low density lipoprotein. , 1973, Biochimica et biophysica acta.
[145] F. del Greco,et al. Lipid abnormalities in renal disease. , 1972, Annals of clinical laboratory science.